Pyxis Oncology (PYXS) Gross Profit (2024 - 2025)

Pyxis Oncology (PYXS) posted quarterly Gross Profit of $8.6 million for Q4 2025, up 206.74% quarter-over-quarter from $2.8 million in Q2 2025.

Pyxis Oncology (PYXS) Gross Profit (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has reported Gross Profit for 2 consecutive years, with $8.6 million the latest figure, recorded in Q4 2025.

In Q4 2025, Gross Profit changed N/A year-over-year to $8.6 million; the TTM figure through Dec 2025 stood at $11.5 million (down 26.81% YoY), while the FY2025 annual figure was $11.5 million, down 26.81% from the prior year.
Gross Profit climbed to $8.6 million in Q4 2025 per PYXS's latest filing, from $2.8 million in the prior quarter.
Across five years, Gross Profit topped out at $15.7 million in Q1 2024 and bottomed at $2.8 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Pyxis Oncology	198.37 Mn	165.38 Mn	-

Download Data